Assemblywoman Dawn Fantasia (R-Sussex), a former English teacher and school administrator, is criticizing the New Jersey ...

Culper Research report argues that the data underpinning its essential tremor program cannot withstand regulatory scrutiny. According to the short report, Praxis engineered its October 2025 results ...

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Praxis Precision Medicines surged after positive Essential3 data for ulixacaltamide in essential tremor, but tolerability issues limit enthusiasm. Ulixacaltamide demonstrated functional benefit, but ...

Shares of biopharmaceutical company Praxis Precision Medicines Inc. soared Thursday, boosted by the successful trial of a new drug to treat movement disorders. The drug, ulixacaltamide, targets ...

Oct 16 (Reuters) - Praxis Precision Medicines (PRAX.O), opens new tab said on Thursday its experimental drug for a type of movement disorder improved patients' ability to perform daily tasks in two ...

Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...

Praxis Labs, a learning development platform, announced its acquisition on Thursday for an undisclosed amount by the leadership and coaching enterprise Torch. “As a small company with fewer than 20 ...

Dryden Brown is a slight man of 29, with a scruffy, reddish beard and a wry, serious demeanor. On the April afternoon we met at the Beverly Hills Hotel, his dark suit seemed out of place in the sunlit ...

Praxis, a self-described “sovereign network” funded by Silicon Valley investors, is looking for at least 10,000 acres (40.5 square kilometers) somewhere in the world to build its first city.

GOSHEN, Ind.--(BUSINESS WIRE)--Praxis Investment Management ™, Inc., a company of Everence ® and a leading faith-based investment manager, today launched its first two exchange-traded funds ...

Ulixacaltamide’s Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by ...